Divestiture

From a huge 10-restaurant deal to stadium snacks, The ONE Group reveals a capital-efficient playbook for expanding its Benihana and STK brands.

After selling its Oklahoma assets, Amplify Energy has eliminated its debt and is now focusing its capital on high-potential Beta and Bairoil fields.

A Mississippi ER doctor launches a national award for student entrepreneurs, but the founder's own history includes a federal conviction and a pardon.

Branded Legacy just wiped out $1M in legacy debt. The move is part of a radical overhaul by new management aimed at rebuilding investor confidence.

Alico pivots from its 125-year citrus legacy to land development, and its CEO is set to face investors with a bold new plan for its 50,000 acres.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

Frontera's new prepayment pact with Chevron shores up its finances and locks in crude sales, highlighting a strategic win in a volatile oil market.

Gogo has launched its anticipated 5G network for business jets, promising a new era of speed. But can its regional advantage hold against global satellite rivals?

As its partnership with Rio Tinto's Nuton ends, Arizona Sonoran will independently advance its massive copper project, betting on strong economics.

Once a cannabis fund, WEDG has completed its rebrand to Nuclear Diamond Batteries, Inc., betting its future on a patented, decades-long power source.

Twin Hospitality ousts CEO Kim Boerema, naming Chairman Andy Wiederhorn as his replacement to navigate a severe debt crisis and restructure the company.

From coal-heavy to fully green, ACEN has completed a landmark transition. Inside the strategy that made it an Asia-Pacific renewable energy leader.

Challenging global giants, a Korean app marketplace has secured the #2 spot by slashing developer fees and rewarding users, rewriting the rules of app economics.

An FDA setback for its new mastitis drug prompts ImmuCell to double down on its profitable calf health franchise, First Defense®, in a major strategic shift.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

Investors holding older Freddie Mac mortgage securities have one year to convert to modern UMBS or risk facing a significant portfolio liquidity crunch.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.